Azul Airlines Wins Court Approval for $2 Billion Debt Restructuring and New Capital Raise 
Mizuho Raises Broadcom Price Target to $450 on Surging AI Chip Demand 
Westpac Director Peter Nash Avoids Major Investor Backlash Amid ASX Scrutiny 
Coca-Cola’s Costa Coffee Sale Faces Uncertainty as Talks With TDR Capital Hit Snag 
United Airlines Flight to Tokyo Returns to Dulles After Engine Failure During Takeoff 
Trello Outage Disrupts Users as Access Issues Hit Atlassian’s Work Management Platform 
SoftBank Eyes Switch Inc as It Pushes Deeper Into AI Data Center Expansion 
SpaceX Edges Toward Landmark IPO as Elon Musk Confirms Plans 
ADB Approves $400 Million Loan to Boost Ease of Doing Business in the Philippines 
Gulf Sovereign Funds Unite in Paramount–Skydance Bid for Warner Bros Discovery 
Nvidia Develops New Location-Verification Technology for AI Chips 
Trump’s Approval of AI Chip Sales to China Triggers Bipartisan National Security Concerns 
Air Transat Reaches Tentative Agreement With Pilots, Avoids Strike and Restores Normal Operations 
Rio Tinto Signs Interim Agreement With Yinhawangka Aboriginal Group Over Pilbara Mining Operations 
SK Hynix Considers U.S. ADR Listing to Boost Shareholder Value Amid Rising AI Chip Demand 
Microsoft Unveils Massive Global AI Investments, Prioritizing India’s Rapidly Growing Digital Market 
Apple App Store Injunction Largely Upheld as Appeals Court Rules on Epic Games Case 
A US district court upheld the validity of Novartis' patent for its top-selling multiple sclerosis (MS) drug Gilenya, rejecting a lawsuit from generic drug maker HEC.
Gilenya is the Swiss drugmaker's No. 2 revenue generator at $738 million in the second quarter.
HEC had sought approval to make a generic copy of Gilenya before the expiration of Novartis' patent with the US Food and Drug Administration (FDA).
The Swiss drugmaker said it continued the injunction against the marketing and sale of Gilenya and other generics granted to it in June 2019.
The FDA approved three generic versions of the Novartis MS treatment in December.
Novartis had settlement agreements with other manufacturers to allow them to launch generic versions of Gilenya before the patent expires in 2027.
